neuro-primary-mental-health-2017-scientifictracks

Page 50

Notes:

allied

academies

International Conference on

NEUROLOGY AND NEUROSCIENCE

MENTAL HEALTH AND PRIMARY CARE

October 16-18, 2017 | Toronto, Canada

J Neurol Neurorehabil Res 2017 | Volume 2 Issue 3

Plasma metabolomic profiles: Insights into cognitive function

Howard J Federoff

University of California, USA

ur group has studied a longitudinal cohort of seniors,

>75 years, to discover and internally validate peripheral

bloodmeasures that can accurately predict, which cognitively

normal subjects will progress to amnestic Mild Cognitive

Impairment (aMCI) or Alzheimer disease (AD) within less

than three years. We initially reported on plasmametabolites

that were accurate as a diagnostic technique for preclinical

AD. We have extended these observations on plasma

metabolomics and have discovered and validated a panel

of 24 analytes that predict phenoconversion to Alzheimer’s

disease with accuracy of >96%. This discovery and internal

validation work has now been externally validated. Finally,

we described a subpopulation with superior neurocognitive

function and discovered a plasma metabolomic signature

that distinguishes this group from normal. I will discuss

the implications of this body of work regarding cognitive

function and its potential implications for dementia. Plasma

metabolomics signatures correlate with cognitive status

and discriminate between at-risk for AD, MCI/AD manifest

disease, and separately identify individuals with superior

cognition.

Speaker Biography

Howard J Federoff is a Vice Chancellor for Health Affairs and CEO of UC Irvine Health.

He oversees the clinical, health education, and research missions. He investigates gene

therapy and neurodegenerative diseases. He has published greater than 250 articles

and serves on the Editorial Boards of five journals. He has chaired the NIH Recombinant

DNA Advisory Committee and the Gene Therapy Resource Program for NHLBI. He

was President of the American Society for Experimental Neurotherapeutics. He has

received his MS, PhD, and MD degrees from the Albert Einstein College of Medicine,

internship, residency, and clinical and research fellowships at Massachusetts General

Hospital/Harvard Medical School. He is a Fellow of the AAAS, National Academy of

Inventors and American Neurological Association.